Calpain inhibitors protect against depolarization-induced neurofilament protein loss of septo-hippocampal neurons in culture.
We examined the effect of a 6 min depolarization with 60 mM KCl and 1.8, 2.8 or 5.8 mM extracellular CaCl2 on neurofilament proteins of high (NF-H), medium (NF-M) and low (NF-L) molecular weight in primary septohippocampal cultures. One day after depolarization, Western blot analyses revealed losses of all three neurofilament proteins. Increasing the extracellular calcium concentration from 1.8 to 5.8 mM CaCl2 in the presence of 60 mM KCl produced increased losses of all three neurofilament proteins to approximately 80% of control values in the absence of cell death. Calcium-dependent losses of the neurofilament proteins correlated with calcium-dependent increases in calpain 1-mediated breakdown products of alpha-spectrin. Calpain inhibitors 1 and 2, applied immediately after depolarization and made available to cultures for 24 h, reduced losses of all three neurofilament proteins to approximately 14% of control values. The protective effects of calpain inhibitors 1 and 2 were influenced by different levels of extracellular calcium. Qualitative immunohistochemical evaluations confirmed semiquantitative Western blot data on neurofilament loss and protection by calpain inhibitors 1 and 2. We propose that brief depolarization causes loss of neurofilament proteins, possibly due to calpain activation. Thus, calpain inhibitors could represent a viable strategy for preserving the cytoskeletal structure of injured neurons.
Kampfl
A
A
Department of Neurosurgery, University of Texas Health Science Center at Houston, 77030, USA.
Zhao
X
X
Whitson
J S
JS
Posmantur
R
R
Dixon
C E
CE
Yang
K
K
Clifton
G L
GL
Hayes
R L
RL
D000818:Animals; D002122:Calcium Chloride / Q000494:pharmacology; D002154:Calpain / Q000037:antagonists & inhibitors* / Q000502:physiology; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D006624:Hippocampus / Q000166:cytology*; D007976:Leupeptins / Q000494:pharmacology*; D008564:Membrane Potentials; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D016900:Neurofilament Proteins / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D012688:Septum Pellucidum / Q000166:cytology*; D013049:Spectrin / Q000378:metabolism
D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D009419:Nerve Tissue Proteins; D016900:Neurofilament Proteins; C089487:acetyl-leucinyl-leucinyl-methional; C063261:acetylleucyl-leucyl-norleucinal; D013049:Spectrin; D011189:Potassium Chloride; D002154:Calpain; D002122:Calcium Chloride